InhaleRx Limited (ASX:IRX)

Market Cap	6.16M
Revenue (ttm)	833.90K -6.4%
Net Income	-1.33M
EPS	-0.01
Shares Out	246.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,000
Average Volume	279,059
Open	0.0250
Previous Close	0.0250
Day's Range	0.0250 - 0.0250
52-Week Range	0.0180 - 0.0480
Beta	-0.44
RSI	52.33
Earnings Date	Feb 26, 2026

About InhaleRx

InhaleRx Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021. InhaleRx Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IRX

Financial Performance

In 2024, InhaleRx's revenue was 401,811, a decrease of -66.63% compared to the previous year's 1.20 million. Losses were -1.21 million, -16.21% less than in 2023.